Michael R. Hayden, Director at Xenon Pharmaceuticals Inc. (XENE), bought 15,000 shares at $2.75 ($41K) on 2017-08-14, disclosed to the SEC on 2017-08-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| IONS | BUY | 2026-07-31 | $1.1M | — | Filing → |
| IONS | BUY | 2025-05-02 | $478K | — | Filing → |
| IONS | BUY | 2024-12-26 | $272K | — | Filing → |